Intraoral pouches and methods of manufacturing the same
The intraoral pouch with a porous shell and specific composition addresses the challenge of temporary relief in oral care products by providing sustained delivery and therapeutic benefits, enhancing oral health through controlled release of active agents.
Patent Information
- Application Number
- PCT/US2026/027770
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-06-18
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Current oral care products provide only temporary relief due to poor retention times and are inconvenient for continuous use, as they are quickly diluted or washed away by saliva, making it difficult to maintain a therapeutic concentration of active ingredients in the oral cavity.
An intraoral pouch with a porous shell and inner cavity containing a composition of xylitol, nano-hydroxyapatite, hyaluronic acid, and other agents, designed for sustained delivery of active agents to the oral mucosa, providing a controlled release mechanism that conforms to mucosal tissue.
The intraoral pouch offers discreet, long-lasting, and effective delivery of therapeutic agents, promoting salivary stimulation, hydration, and oral health benefits, suitable for various oral conditions without disrupting daily activities.
Smart Images

Figure US2026027770_19112026_PF_FP_ABST
Abstract
Description
[0001] INTRAORAL POUCHES AND METHODS OF MANUFACTURING THE SAME
[0002] FIELD OF THE INVENTION
[0003] The subject matter of the present disclosure relates generally to intraoral pouches having a powder composition therein and a method of manufacturing the same.
[0004] BACKGROUND
[0005] Standard medical interventions and over-the-counter remedies for addressing a variety of oral care conditions, such as mucosal dehydration, aphthous ulcers, halitosis, and post-surgical wounds, frequently rely on transient delivery methods. Maintaining optimal oral health and providing localized therapy often requires the sustained delivery of active agents directly to the oral mucosa. Common modalities for delivering these agents include oral sprays, dissolvable lozenges, topical gels, and mouthwashes. While these modalities are widely used, they induce inherent technical and clinical limitations. Specifically, current treatments provide only temporary relief, suffer from poor retention times within the oral cavity, and may be inconvenient for continuous, prolonged use across varying clinical indications. The oral environment is dynamic, characterized by the constant flow of saliva, mechanical action of the tongue and cheeks during speech and mastication, and the act of swallowing. These factors contribute to the rapid clearance of topically applied substances, making it difficult to maintain a therapeutic concentration of an active ingredient at a target site for a sufficient duration.
[0006] Furthermore, delivering sustained therapeutic relief to the oral cavity without disrupting daily activities remains a significant challenge. Lozenges actively dissolve, requiring the user to continually manage the physical volume and shifting position of the lozenge within their mouth, while gels and sprays are quickly diluted and washed away by residual saliva. Consequently, there remains a need for a discreet, long-lasting, and effective delivery system for localized oral care formulations, including mucosal moisturizers, wound-healing agents, and antibacterial compounds. An intraoral pouch that conforms to the mucosal tissue and delivers active agents slowly and effectivelyover time may provide improved therapeutic outcomes for patients suffering from a wide array of oral discomforts.
[0007] Accordingly, an improved delivery system for the oral cavity to provide a sustained release of active agents directly to the oral mucosa is desired in the art. In particular, a versatile platform that can be adapted to deliver various compositions to address a variety of oral health issues would be particularly advantageous.
[0008] SUMMARY
[0009] Objects and advantages of the invention will be set forth in part in the following description, or may be obvious from the description, or may be learned through practice of the present disclosure.
[0010] The present disclosure is directed to an intraoral pouch. The intraoral pouch includes a porous pouch made of a shell and an inner cavity and a composition within the inner cavity of the porous pouch. The composition includes about 20 wt.% to about 80 wt.% xylitol; about 0.5 wt.% to about 25 wt.% nano-hydroxyapatite (nHA); and about 0.2 wt.% to about 25 wt.% hyaluronic acid.
[0011] In aspects, the composition may be a powder composition.
[0012] In some aspects, the composition may include about 40 wt.% to about 60 wt.% xylitol; about 1.0 wt.% to about 10 wt.% nano-hydroxyapatite (nHA); about 1.0 wt.% to about 10 wt.% hyaluronic acid; and about 0.2 wt.% to about 1.0 wt.% citric acid.
[0013] In aspects, the citric acid may have a particle size of about 50 urn to about 100 urn.
[0014] In aspects, the hyaluronic acid may have a molecular weight of about 10,000 g / mol to about 1,000,000 g / mol.
[0015] In some aspects, the hyaluronic acid have molecular weight of about 10,000 g / mol to about 100,000 g / mol.
[0016] In aspects, the hyaluronic acid has a particle size of about 1 urn to about 100 urn. In some aspects, the nano-hydroxyapatite may have a particle size of about 20 nm to about 200 nm.In some aspects, the composition may further include at least one of a binder, natural flavor agent, a sweetener, a flow agent, a buffering agent, or a moisture control agent.
[0017] In aspects, the flow agent may include rice hull powder, silicon dioxide, or maltodextrin.
[0018] In some aspects, the flow agent may include rice hull powder having a particle size of about 50 urn to about 500 urn.
[0019] In aspects, the natural flavor agent may include mint or citric acid.
[0020] In some aspects, the sweetener may include Stevia rebaudiana or monk fruit. In aspects, the sweetener may include Stevia rebaudiana and may have a particle size of about 1 urn to about 50 urn.
[0021] In some aspects, the buffering agent may include sodium bicarbonate or magnesium carbonate.
[0022] In aspects, the moisture control agent may include water, MCT oil, glycerin, or a combination thereof.
[0023] In some aspects, the intraoral pouch may further include microcrystalline cellulose having a particle size of about 1 urn to about 300 urn.
[0024] In aspects, the composition may further include less than about 1 wt.% Aloe vera powder.
[0025] In some aspects, the shell of the porous pouch may define a pore size of about 20 urn to about 200 urn.
[0026] In aspects, the shell of the porous pouch may include a biocompatible fiber. In some aspects, the biocompatible fiber may include cellulose, corn fiber, or a biodegradable polymer.
[0027] In aspects, the porous pouch may include a non-woven semi-permeable membrane formed from the biocompatible fiber.
[0028] In some aspects, a ratio of a width of the porous pouch to a length of the porous pouch may be in a range from about 1 :2 to about 1 :2.5.
[0029] In aspects, the intraoral pouch may be free from tobacco and nicotine.
[0030] Moreover, the present disclosure is directed to a method of manufacturing an intraoral pouch. The method includes providing a porous pouch, the porous pouchdefining a first end and a second end, the second end being sealed and the first end defining an opening. The method also includes providing a composition and depositing the composition into the porous pouch via the opening defined by the first end of the porous pouch. Further, the method includes sealing the first end of the porous pouch. The composition includes about 20 wt.% to about 80 wt.% of a sugar alcohol; about 0.5 wt.% to about 25 wt.% of a mineralizing agent; about 0.5 wt.% to about 25 wt.% of a humectant; and a natural flavor agent.
[0031] In aspects, the composition may be a powder composition.
[0032] In some aspects, the sugar alcohol may include xylitol.
[0033] In aspects, the mineralizing agent may include nano-hydroxyapatite (nHA).
[0034] In some aspects, the humectant may include hyaluronic acid.
[0035] In aspects, the step of depositing the composition into the porous pouch may include depositing about 100 mg to 10,000 mg of the composition into the porous pouch.
[0036] In some aspects, the composition may further include at least one of a sweetener, a flow agent, a buffering agent, or a moisture control agent.
[0037] In aspects, the present disclosure is directed to a composition for oral health. The composition includes about 20 wt.% to about 80 wt.% of a sugar alcohol; about 0.5 wt.% to about 25 wt.% of a mineralizing agent; and about 0.2 wt.% to about 25 wt.% hyaluronic acid.
[0038] In some aspects, the composition may be a powder composition.
[0039] In aspects, the sugar alcohol may include xylitol.
[0040] In some aspects, the mineralizing agent may include nano-hydroxyapatite (nHA). In aspects, the hyaluronic acid may have a molecular weight of about 10,000 g / mol to about 1 ,000,000 g / mol.
[0041] In some aspects, the composition may include about 40 wt.% to about 60 wt.% of the sugar alcohol; about 1.0 wt.% to about 10 wt.% of the mineralizing agent; and about 1.0 wt.% to about 10 wt.% hyaluronic acid.
[0042] In aspects, the composition may further include about 0.2 wt.% to about 1.0 wt.% of a natural flavor agent, wherein the natural flavor agent may include mint or citric acid.In some aspects, the mineralizing agent may include nano-hydroxyapatite having a particle size of about 20 nm to about 200 nm, and the hyaluronic acid may have a particle size of about 1 urn to about 100 urn.
[0043] In aspects, the composition may further include at least one of a natural flavor agent, a sweetener, a flow agent, a buffering agent, or a moisture control agent.
[0044] Furthermore, the present disclosure is directed to an intraoral pouch for treatment of aphthous ulcers. The intraoral pouch includes a porous pouch defining a shell and an inner cavity, and a composition within the inner cavity of the porous pouch. The composition includes about 0.25 wt.% to about 10.0 wt.% of an analgesic; about 5.0 wt.% to about 80.0 wt.% of an antibacterial agent; an anti-inflammatory agent; and a humectant.
[0045] In aspects, the analgesic may include benzocaine, a natural anesthetic, or a combination thereof.
[0046] In some aspects, the humectant may include hyaluronic acid, hydroxypropyl cellulose, or a combination thereof.
[0047] In aspects, the antibacterial agent may include zinc acetate, xylitol or a combination thereof.
[0048] In some aspects, the anti-inflammatory agent may include glycyrrhizin, curcumin, Boswellia extract, or a combination thereof.
[0049] In aspects, the composition may further include a soothing agent, wherein the soothing agent may include Aloe vera, chamomile, or a combination thereof.
[0050] In some aspects, the composition may further include a buffering agent, wherein the buffering agent may include magnesium carbonate, sodium bicarbonate, or a combination thereof.
[0051] In aspects, the composition may further include a filler, wherein the filler may include microcrystalline cellulose.
[0052] In some aspects, the composition may further include a binder, wherein the binder may include MCT oil, glycerin, or a combination thereof.
[0053] In aspects, the composition may have a total weight of about 0.5 grams to about 2.0 grams.In aspects, the present disclosure is directed to an intraoral pouch for post-surgical oral care. The intraoral pouch includes a porous pouch defining a shell and an inner cavity, and a composition within the inner cavity of the porous pouch. The composition includes about 0.01 wt.% to about 5.0 wt.% of a hemostatic agent; an antiinflammatory agent; and a humectant.
[0054] In aspects, the humectant may include hyaluronic acid.
[0055] In some aspects, the hemostatic agent may include chitosan, calcium carbonate, tannic acid, alginate, kaolin, or a combination thereof.
[0056] In aspects, the hemostatic agent may include about 0.1 wt.% to about 5.0 wt.% of chitosan, about 0.1 wt.% to about 5.0 wt.% of calcium carbonate, about 0.01 wt.% to about 0.5 wt.% of tannic acid, about 0.1 wt.% to about 3.0 wt.% of alginate, about 0.1 wt.% to about 3.0 wt.% of kaolin, or a combination thereof.
[0057] In some aspects, the anti-inflammatory agent may include curcumin, Boswellia extract, Aloe vera, or a combination thereof.
[0058] In aspects, the composition may further include an analgesic, wherein the analgesic may include benzocaine, clove oil, or a combination thereof.
[0059] In some aspects, the composition may further include an antibacterial agent, wherein the antibacterial agent may include xylitol, acetic acid, or a combination thereof.
[0060] In aspects, the composition may further include a buffering agent, wherein the buffering agent may include magnesium carbonate, sodium bicarbonate, or a combination thereof.
[0061] In some aspects, the composition may further include a binder, wherein the binder may include hydroxypropyl cellulose-L, MCT oil, glycerin, or a combination thereof.
[0062] In aspects, the composition may further include a filler, wherein the filler may include microcrystalline cellulose.
[0063] In some aspects, the composition may have a total weight of about 1.0 gram to about 10.0 grams.
[0064] In aspects, the present disclosure is directed to an intraoral pouch for the treatment of halitosis. The intraoral pouch includes a porous pouch defining a shell and an inner cavity, and a composition within the inner cavity of the porous pouch. Thecomposition includes about 20.0 wt.% to about 85.0 wt.% of an antibacterial agent; about 0.2 wt.% to about 5.0 wt.% of a humectant; and a probiotic.
[0065] In some aspects, the antibacterial agent may include xylitol.
[0066] In aspects, the antibacterial agent may further include zinc acetate, zinc gluconate, or a combination thereof.
[0067] In some aspects, the humectant may include hyaluronic acid.
[0068] In aspects, the probiotic may include Streptococcus salivarius K12, Weissella cibaria, or a combination thereof.
[0069] In some aspects, the probiotic may be present in an amount from 10 billion colony-forming units (CFU) to 300 billion CFU.
[0070] In aspects, the composition may have a moisture content of about 0% to about 20%.
[0071] In some aspects, the composition may further include a binder, wherein the binder may include hydroxypropyl cellulose-L, MCT oil, glycerin, or a combination thereof.
[0072] In aspects, the composition may further include citric acid.
[0073] In some aspects, the composition may further include a filler, wherein the filler may include microcrystalline cellulose.
[0074] In aspects, the composition may further include a sweetener, wherein the sweetener may include Stevia rebaudiana.
[0075] In some aspects, the composition may have a total weight of about 0.5 grams to about 1.0 gram.
[0076] These and other features, aspects, and advantages of the present disclosure will become better understood with reference to the following description and appended claims. The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the description, serve to explain the principles of the present disclosure.
[0077] BRIEF DESCRIPTION OF THE DRAWINGSA full and enabling disclosure of the present disclosure, including the best mode thereof, directed to one of ordinary skill in the art, is set forth in the specification, which makes reference to the appended figures, in which:
[0078] FIG. 1 illustrates a perspective view of an intraoral pouch in accordance with aspects of the present disclosure;
[0079] FIG. 2 illustrates a cross-sectional view of the intraoral pouch taken along line 2-2 of FIG. 1, particularly illustrating the inner cavity and the composition disposed therein; and
[0080] FIG. 3 illustrates a block flow diagram of an embodiment of a method of manufacturing an intraoral pouch in accordance with aspects of the present disclosure.
[0081] DETAILED DESCRIPTION
[0082] Reference now will be made in detail to embodiments of the disclosure, one or more examples of which are illustrated in the drawings. Each example is provided by way of explanation of the disclosure, not limitation of the disclosure. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made in the present disclosure without departing from the scope or spirit of the disclosure. For instance, features illustrated or described as part of one embodiment may be used with another embodiment to yield a still further embodiment. Thus, it is intended that the present disclosure covers such modifications and variations as come within the scope of the appended claims and their equivalents. The detailed description uses numerical and letter designations to refer to features in the drawings. Like or similar designations in the drawings and description have been used to refer to like or similar parts of the disclosure.
[0083] As used herein, the terms “first”, “second”, and “third” may be used interchangeably to distinguish one component from another and are not intended to signify location or importance of the individual components. The singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. The terms “coupled,” “fixed,” “attached to,” and the like refer to both direct coupling, fixing, or attaching, as well as indirect coupling, fixing, or attaching through one or more intermediate components or features, unless otherwise specified herein. As usedherein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of features is not necessarily limited only to those features but may include other features not expressly listed or inherent to such process, method, article, or apparatus. Further, unless expressly stated to the contrary, “or” refers to an inclusive- or and not to an exclusive-or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
[0084] Terms of approximation, such as “about,” “generally,” “approximately,” or “substantially,” include values within ten percent greater or less than the stated value. When used in the context of an angle or direction, such terms include within ten degrees greater or less than the stated angle or direction. For example, “generally vertical” includes directions within ten degrees of vertical in any direction, e.g., clockwise or counter-clockwise. Further, when a plurality of ranges are provided, any combination of a minimum value and a maximum value described in the plurality of ranges are contemplated by the present disclosure. For example, if ranges of “from about 20% to about 80%” and “from about 30% to about 70%” are described, a range of “from about 20% to about 70%” or a range of “from about 30% to about 80%” are also contemplated by the present disclosure.
[0085] When used to describe a shape, the term “generally” is used to describe an object having the overall appearance of a shape and may include slight deviations from the exact shape, such as including one or more protrusions or indentations in the outline of the shape. For example, the term “generally rectangular” may be used to describe an object having the overall appearance of a rectangle having two sets of parallel sides and four right angles, but may include one or more indentations and / or protrusions along the parallel sides and / or slight variations in the right angles at the corners. For instance, a rectangular shape having slightly rounded comers may be described as “generally rectangular” as used herein. As a further example, a “generally cylindrical” shape may have the characteristics of a cylinder (a geometric figure with straight parallel sides and a circular or oval cross section) but may have minor variations (e.g.,the sides may be + / - 10 degrees from parallel; the cross section may be generally circular or oval but may have minor concave or convex features).
[0086] Unless specified or limited otherwise, the terms “mounted,” “connected,” “supported,” and “coupled” and variations thereof are used broadly and encompass both direct and indirect mountings, connections, supports, and couplings. Additionally, unless specified or limited otherwise, the terms “lower,” “upper,” and variations thereof are used broadly for the purposes of describing relative positions of elements of the illustrated embodiments.
[0087] Generally speaking, the present disclosure is directed to addressing the deficiencies of conventional oral care products by providing an intraoral pouch configured for safe, discreet, and effective sustained delivery of active agents to the oral cavity. The pouch may be designed to be placed in the buccal (i.e. , the cheek or area inside the mouth of a user) or sublingual space (i.e., under the tongue of a user), where it may reside comfortably for an extended period (e.g., 1 minute to 12 hours). During this time, the intraoral pouch may gradually release a specialized composition that may provide a synergistic combination of salivary stimulation, long-lasting hydration, and therapeutic oral health benefits (e.g., infection, gum disease or decay, tooth decay, cavity prevention, or oral drug release). Unlike conventional sprays or lozenges that provide only fleeting relief, the intraoral pouch may be free from tobacco and nicotine. Moreover, the intraoral pouch may create a continuous, favorable oral environment, making it uniquely suitable for managing a variety of oral conditions.
[0088] Referring now to FIGS. 1-3, the various features of the intraoral pouch, and methods of forming the same, contemplated by the present disclosure will be described in more detail.
[0089] Turning now to FIGS. 1-2, wherein identical numerals indicate the same elements throughout the figures, FIG. 1 illustrates an exemplary embodiment of an intraoral pouch 100 in accordance with aspects of the present disclosure. The intraoral pouch 100 may include a porous pouch 101 defining a shell 102 and an inner cavity 112. In aspects, the porous pouch 101 may be designed for placement within an oral cavity of a user, such as in the buccal sulcus between the cheek and gum of the user for a period of time. In aspects, the period of time may be about 1 minute to 12 hours,such as 10 minutes to about 120 minutes. In aspects, the porous pouch 101 may include a porous fiber pouch formed of a natural or synthetic fiber.
[0090] In aspects, the porous pouch 101 may define a first end 101 A and a second end 101B. In aspects, the porous pouch 101 may define a width 106 and a length 107 (i.e. , measured from the first end 101 A to the second end 101 B). In aspects, the width 106 of the porous pouch 101 may be 10 mm to 20 mm, such as 15 mm to 18 mm. In aspects, the length 107 of the porous pouch 101 may be 30 mm to 40 mm. Additionally or alternatively, a ratio of the width 106 of the porous pouch 101 to the length 107 of the porous pouch 101 may be about 1 :2 to about 1 :2.5.
[0091] Moreover, the porous pouch 101 may include a seal 108 so as to enclose the intraoral pouch 100. Additionally or alternatively, prior to forming the seal 108, the porous pouch 101 may include an opening 110 on the first end 101 A or the second end 101 B. In aspects, the seal 108 may include a first seal 108A and a second seal 108B. The first seal 108A may be positioned adjacent to the first end 101 A of the porous pouch 101 and the second seal 108B may be positioned adjacent to the second end 101 B of the porous pouch 101. In aspects, the first seal 108A may be positioned toward the end of the porous pouch 101 , and the second seal 108A may be positioned toward an opposite end of the porous pouch 101. Additionally or alternatively, the intraoral pouch 100 may include a seal 108 along a perimeter (not shown) of the porous pouch 101. In aspects, the seal(s) 108 may be formed by methods known in the art, such as heat sealing, ultrasonic welding, or an alternative method which is sufficient to create a durable bond without the use of extraneous chemical adhesives. In aspects, the seal(s) 108 may have a width 109 of 1 mm to 5 mm.
[0092] The shell 102 of the porous pouch 101 may be constructed from a biocompatible fiber. Suitable materials for the biocompatible fiber may include, but are not limited to, plant-based fabrics such as cellulose (e.g., from wood pulp), corn fiber, or other similar materials. In aspects, the biocompatible fiber may include a flavor-permeable, nondissolving fiber, such as a plant-based fabric, a tea-bag paper, or a hydrocolloid mesh. In aspects, the biocompatible fiber may include a biodegradable polymer. In aspects, the material of the shell 102 may be selected to be soft and pliable to conform to thecontours of the oral mucosa while being sufficiently robust to maintain its structural integrity during the intended period of use.
[0093] In aspects, the shell 102 may include a non-woven semi-permeable membrane. This membrane may be defined by a plurality of pores (not shown). In aspects, the shell 102 of the porous pouch 101 may define a pore size in a range from about 20 pm to about 200 pm. In aspects, the shell 102 may be specifically selected so as to define a pore size large enough to permit the ingress of a user's saliva, water, or other liquids into the porous pouch 101 and the subsequent egress of dissolved active agents from within, but small enough to substantially retain undissolved particles of the composition 114 as described below. Additionally or alternatively, the shell 102 may be configured to prevent leakage of solid granules, thereby facilitating a controlled, sustained release of the active ingredients while preventing the egress of the solid granules into the oral cavity of the user.
[0094] More particularly, as shown in FIG. 2, the porous pouch 101 may define an inner cavity 112 having the composition 114 therein, such as a powder composition. In aspects, the powder composition may be an anhydrous (i.e. , without water, or dry) powder composition. In aspects, the use of the powder composition may be configured to promote the chemical stability and extend the shelf life of the active ingredients of the composition 114 by inhibiting degradation pathways such as hydrolysis. Additionally, the powder composition may be configured to promote the sustained-release mechanism of the intraoral pouch 100. For instance, the anhydrous nature may require saliva to first ingress into the inner cavity 112 to dissolve the particles of the composition 114, thereby creating a controlled, gradual diffusion of active agents out of the porous pouch
[0095] 101 over an extended period.
[0096] Additionally or alternatively, the composition 114 may be formulated to address a variety of oral conditions. In aspects, the composition 114 may be a first composition 114A formulated for the alleviation of xerostomia. In such an aspect, the first composition 114A may include a sugar alcohol, such as xylitol. The sugar alcohol (e.g., xylitol) may be present in an amount of about 20 wt.% to about 80 wt.% of the composition 114. Additionally or alternatively, the sugar alcohol (e.g., xylitol) may be present in an amount of about 40 wt.% to about 60 wt.% of the composition 114. Inaspects, xylitol may be utilized to stimulate the salivary glands and inhibit cariogenic bacteria within the oral cavity. By employing a high concentration of xylitol, the intraoral pouch 100 may be configured to provide sustained, non-cariogenic salivation response so as to mitigate the adverse effects of dry mouth, gum disease, or tooth decay The first composition 114A may further include a mineralizing agent, such as nano-hydroxyapatite (nHA). The mineralizing agent may be present in an amount of about 0.5 wt.% to about 25 wt.% of the composition 114. In further aspects, the mineralizing agent may be present in an amount of about 1.0 wt.% to about 10 wt.% of the first composition 114A. In aspects, the mineralizing agent may have a specific particle size so as to maximize clinical efficacy and ensure optimal integration into the dental structure. In aspects, the mineralizing agent may have a particle size of about 20 nm to about 200 nm. The mineralizing agent (e.g., nHA) may be configured to structurally support enamel repair, strengthen the teeth against decay, and provide a smooth oral feel to the user.
[0097] The first composition 114A may further include a humectant, such as hyaluronic acid. The humectant may be present in an amount of about 0.2 wt.% to about 25 wt.% of the first composition 114A. In further aspects, the humectant may be present in an amount of about 1.0 wt.% to about 10 wt.% of the first composition 114A. The humectant (e.g., hyaluronic acid) may define a molecular weight of about 10,000 g / mol to about 1,000,000 g / mol. In aspects, the molecular weight may be about 10,000 g / mol to about 100,000 g / mol. Additionally or alternatively, the humectant may be provided in a high molecular weight form ranging from about 0.5 million g / mol to about 1.5 million g / mol. In aspects, the humectant may have a particle size of about 1 pm to about 100 pm. The humectant may be configured to deeply hydrate and coat the oral mucosa, acting as a lubricant so as to retain moisture in the oral tissue of the user and act as a barrier to reduce discomfort associated with severe xerostomia.
[0098] To further promote a natural physiological response, the first composition 114A may include a natural flavor agent, such as citric acid. The natural flavor agent may be present in an amount of about 0.2 wt.% to about 1.0 wt.% of the first composition 114A. In aspects, the natural flavor agent has a particle size of about 50 pm to about 100 pm. Additionally or alternatively, the natural flavor agent may be configured to activelystimulate the taste receptors of the user, thereby promoting a natural increase in saliva flow and providing an optimal flavor balance to the overall composition 114.
[0099] In aspects, the composition 114 may further include a balance of other elements, such as at least one of a natural flavor agent (e.g., mint or citral), a sweetener (e.g., Stevia rebaudiana or monk fruit), a flow agent (e.g., rice hull powder, silicon dioxide, or maltodextrin), a buffering agent (e.g., sodium bicarbonate or magnesium carbonate), a filler, a moisture control agent (e.g., water, glycerin, medium-chain triglyceride (MCT) oil, or a combination thereof), or a binder (e.g., MCT oil, or hydroxypropyl cellulose-L (HPC-L), glycerin, or a combination thereof). The flow agent may have a particle size of about 50 pm to about 500 pm. The sweetener may have a particle size of about 1 pm to about 50 pm. In aspects, the buffering agent may be configured to stabilize the pH of the saliva and protect enamel. In aspects, the moisture control agent may have a particle size of about 10 pm to about 200 pm.
[0100] The first composition 114A may additionally or alternatively include a filler, such as microcrystalline cellulose, having a particle size of about 1 pm to about 300 pm. Additionally or alternatively, the first composition 114A may optionally include less than about 1 wt.% Aloe vera powder so as to provide supplementary soothing properties.
[0101] Additionally or alternatively, the composition 114 may be a second composition 114B formulated for the treatment of aphthous ulcers. In aspects, the second composition 114B may be formulated so as to create a protective physical barrier over the aphthous ulcer so as to shield an exposed nerve ending and underlying tissue from the oral environment while simultaneously delivering agents to manage pain, inflammation, and infection risk.
[0102] In such an aspect, the second composition 114B may include an analgesic, such as benzocaine, a natural anesthetic, or a combination thereof. In aspects, the natural anesthetic may be plant derived, such as clove oil, aloe vera, or peppermint. The analgesic may be present in an amount of about 0.25 wt.% to about 10.0 wt.% of the second composition 114B. In aspects, the second composition 114B may include about 1 mg to about 200 mg of the analgesic, such as about 5 mg to 50 mg. In aspects, the analgesic may be configured to numb the ulcerated tissue and reduce localized pain for the user.In aspects, the second composition 114B may include an antibacterial agent, such as zinc acetate, xylitol, or a combination thereof. The antibacterial agent may be present in an amount of about 5.0 wt.% to about 80.0 wt.% of the second composition 114B. In aspects, the second composition may include about 100 mg to about 700 mg of the antibacterial agent. In aspects, the antibacterial agent may be configured to prevent secondary bacterial infections at the ulcer site.
[0103] In aspects, the second composition 114B may include an anti-inflammatory agent, such as glycyrrhizin, curcumin, Boswellia extract, or a combination thereof. The anti-inflammatory agent may be configured to reduce localized swelling and accelerate the healing of the oral mucosa.
[0104] Additionally or alternatively, the second composition 114B may include a humectant, such as hyaluronic acid, hydroxypropyl cellulose, or a combination thereof. In aspects, upon hydration, the humectant may be configured to form a protective physical barrier (e.g., a hydrogel) over the ulcer so as to shield the exposed ulcer from further irritation within the oral cavity. In aspects, the second composition 114B may further include a soothing agent, such as Aloe vera, chamomile, or a combination thereof.
[0105] In this configuration, the second composition 114B may define a total weight sufficient to cover the surgical site or be packed within an extraction socket, thereby holding the hemostatic and therapeutic agents in direct and sustained contact with the target tissue. In aspects, the second composition 114B may define a total weight of about 0.5 grams to about 2.0 grams.
[0106] Additionally or alternatively, the second composition 114B may include a buffering agent. In aspects, the buffering agent may include magnesium carbonate, sodium bicarbonate, or a combination thereof. In aspects, the buffering agent may be configured to maintain a physiologically favorable pH.
[0107] In aspects, the second composition 114B may include at least one of a natural flavor agent (e.g., citric acid or mint), a filler (e.g., microcrystalline cellulose), a binder (e.g., MCT oil, glycerin, or a combination thereof), or a sweetener (e.g., Stevia rebaudiana or monk fruit).In aspects, the second composition 114B may define a total weight sufficient to form a durable barrier and deliver a therapeutic dose of the active agents over an extended period. In aspects, the second composition 114B may define a total weight of about 0.5 grams to about 2.0 grams.
[0108] In other aspects, the composition 114 may be a third composition 114C formulated for post-surgical oral care. By way of non-limiting example, the third composition 114C may be configured to provide a wound healing environment following procedures such as tooth extractions, biopsies, or implant placements. In such an aspect, the third composition 114C may include a plurality of active agents so as to manage bleeding, pain, inflammation, and infection risk.
[0109] In aspects, the third composition 114C may include a hemostatic agent, such as chitosan, calcium carbonate, tannic acid, alginate, kaolin, or a combination thereof. The hemostatic agent may be present in an amount of about 0.01 wt.% to about 5.0 wt.% of the third composition 114C. In aspects, the hemostatic agent may include about 10 mg to about 50 mg of chitosan, about 10 mg to about 50 mg of calcium carbonate, about 1 mg to about 5 mg of tannic acid, about 10 mg to about 30 mg of alginate, about 10 mg to about 30 mg of kaolin, or a combination thereof. Additionally or alternatively, the hemostatic agent may include about 0.1 wt.% to about 5.0 wt.% of the chitosan, about 0.1 wt.% to about 5.0 wt.% of the calcium carbonate, about 0.01 wt.% to about 0.5 wt.% of the tannic acid, about 0.1 wt.% to about 3.0 wt.% of the alginate, about 0.1 wt.% to about 3.0 wt.% of the kaolin, or a combination thereof. In aspects, the hemostatic agent may be configured to control post-operative bleeding and promote hemostasis at a surgical site.
[0110] Additionally or alternatively, the third composition 114C may include an antiinflammatory agent, such as curcumin, Boswellia extract, Aloe vera, or a combination thereof. In aspects, the anti-inflammatory agent may be configured to reduce local swelling thereby alleviating pressure on the wound of the user.
[0111] Additionally or alternatively, the third composition 114C may include a humectant, such as hyaluronic acid. The humectant may be configured to maintain a moist wound environment, thereby facilitating cellular migration, promoting re-epithelization, and reducing scarring of the user. In aspects, the humectant may form aviscous hydrogel so as to provide a protective, lubricating barrier over the wound of the user.
[0112] In aspects, the third composition 114C may additionally or alternatively include an analgesic, such as benzocaine, clove oil, or a combination thereof. In aspects, the analgesic may be configured to act as a local anesthetic so as to block nerve signals of the user thereby promoting the management of post-surgical pain and discomfort of the user.
[0113] In aspects, the third composition 114C may include an antibacterial agent, such as xylitol, acetic acid, or a combination thereof. The antibacterial agent may be configured to maintain a sterile wound environment and reduce a microbial load so as to prevent post-surgical infections.
[0114] Additionally or alternatively, the third composition 114C may include a buffering agent, such as magnesium carbonate, sodium bicarbonate, or a combination thereof. In aspects, the buffering agent may be configured to maintain a physiologically favorable pH in the vicinity of the wound of the user.
[0115] In aspects, the third composition 114C may include a binder, such as hydroxypropyl cellulose-L, MCT oil, glycerin, or a combination thereof. Additionally or alternatively, the third composition 114C may include a filler, such as microcrystalline cellulose.
[0116] In this post-surgical configuration, the third composition 114C may define a total weight in a range from about 1.0 gram to about 10.0 grams.
[0117] Additionally or alternatively, the composition 114 may be a fourth composition 114D formulated for the treatment of halitosis (i.e. , bad breath). In such an aspect, the fourth composition 114D may include an antibacterial agent, such as xylitol. In aspects, the xylitol may be configured to inhibit or prevent the growth and metabolism of harmful oral bacteria, including those that produce volatile sulfur compounds (VSCs).
[0118] Additionally or alternatively, the antibacterial agent may include a zinc compound, such as zinc acetate, zinc gluconate, or a combination thereof. In aspects, the zinc compound may be configured to chemically bind to and neutralize VSCs. In aspects, the antibacterial agent may be present in an amount of about 20.0 wt.% to about 85.0 wt.%of the fourth composition 114D. In aspects, the antibacterial agent may be designed to neutralize odor-causing bacteria within the oral cavity.
[0119] The fourth composition 114D may further include a humectant, such as hyaluronic acid. The humectant may be present in an amount of about 0.2 wt.% to about 5.0 wt.% of the fourth composition 114D. In aspects, the humectant may be configured to alleviate a temporary drying sensation and improve the mouthfeel of the product.
[0120] To actively restore and balance the pH of the oral microbiome, the fourth composition 114D may further include a probiotic, such as Streptococcus salivarius K12, Weissella cibaria, or a combination thereof. The probiotic may be present in an amount ranging from 10 billion colony-forming units (CFU) to 300 billion CFU. In aspects, the probiotic may be utilized to introduce beneficial bacterial strains that outcompete the VSC-producing bacteria responsible for halitosis. By way of non-limiting example, these probiotics may help to establish a healthier, less odorous microbiome over time by colonizing oral surfaces.
[0121] Additionally or alternatively, the fourth composition 114D may include at least one of a binder (e.g., hydroxypropyl cellulose-L (HPC-L), MCT oil, glycerin, ora combination thereof), a filler (e.g., microcrystalline cellulose), or a sweetener (e.g., Stevia rebaudiana). Additionally or alternatively, the fourth composition 114D may include a natural flavor agent, such as citric acid.
[0122] In aspects, the fourth composition 114D may define a moisture content of about less than 20%, such as less than 5%. In aspects, the fourth composition may define a moisture content of about 0% to about 20%, such as about 0% to about 5%. The moisture content limitation may be configured to preserve the viability of the live probiotic cultures during manufacturing and extended storage. In this halitosis configuration, the fourth composition 114D may define a total weight sufficient to provide a discrete and effective dose for daily use. In aspects, the fourth composition 114D may define a total weight of about 0.5 grams to about 1.0 gram.
[0123] To ensure clarity, reproducibility, and a definite scope for the parameters described and claimed herein, the following standard testing procedures are provided as examples. Unless otherwise specified, the values for molecular weight, particle size,pore size, and moisture content recited herein may be determined according to one or more of the exemplary methods outlined below, or their equivalents as understood by one of ordinary skill in the art.
[0124] The weight-average molecular weight (Mw) of polymers such as hyaluronic acid may be determined using Size-Exclusion Chromatography with Multi-Angle Laser Light Scattering (SEC-MALLS). This absolute method can provide molecular weight distribution without reliance on column calibration with polymer standards. A suitable system may include an HPLC (e.g., Agilent 1260 Infinity II) coupled with a multi-angle light scattering detector (e.g., a DAWN® from Wyatt Technology) and a differential refractive index (dRI) detector. Samples may be dissolved in a suitable mobile phase, such as a phosphate-buffered saline solution, and eluted through an appropriate SEC column set (e.g., TSKgel® G5000PWxl). Data may be analyzed using specialized software (e.g., ASTRA® software from Wyatt Technology) to calculate the Mw.
[0125] Alternatively, the molecular weight may be determined by Size-Exclusion Chromatography with conventional calibration (SEC-HPLC / GPC) using pullulan standards.
[0126] Unless otherwise specified, particle size and particle size distribution may be measured by laser diffraction, for example, in accordance with ISO 13320. A suitable instrument for this measurement is a Malvern Mastersizer 3000. For measurement, samples may be dispersed in a suitable medium (e.g., air for dry powders or a nonreacting liquid carrier) to form a stable suspension and passed through a laser beam. The particle size distribution may then be calculated from the resulting light scattering pattern using the Mie or Fraunhofer theory. For particles in the nanometer range, such as the nano-hydroxyapatite described herein (e.g., 20 nm to 200 nm), particle size may be determined by Dynamic Light Scattering (DLS) per ISO 22412, or alternatively, by direct imaging using Transmission Electron Microscopy (TEM).
[0127] The pore size and pore size distribution of the porous pouch shell (102) may be determined by Capillary Flow Porometry, for example, in accordance with ASTM F316-03 (2011). In such a method, the sample may be wet with a low-surface-tension liquid (e.g., Porefil®). Pressurized gas may then be applied to one side of the sample, and the flow rate of gas through the sample is measured as a function of differential pressure.The pressure at which the first continuous bubble appears may determine the maximum pore size (Bubble Point), and the complete pressure / flow curve may be used to calculate the mean flow pore size and the pore size distribution.
[0128] The moisture content of the composition (e.g., composition 114D) may be determined by Karl Fischer titration, for example, using Coulometric Titration as described in USP <921 > Method 1c. This method is highly specific for water and is suitable for accurately measuring low moisture levels. For this determination, a sample of the powder composition may be introduced into the titration cell, and the amount of water is determined by the quantity of electricity required to generate the titrant.
[0129] Referring now to FIG. 3, a flow diagram of an exemplary method 200 of manufacturing an intraoral pouch is provided. The method 200 of FIG. 3 may be utilized to manufacture the intraoral pouch 100 described herein. Accordingly, it will be appreciated that the method 200 may generally be used to assemble the intraoral pouch 100 and formulate the composition 114 to accommodate any of the various clinical embodiments described above (e.g., the first composition 114A, the second composition 114B, the third composition 114C, or the fourth composition 114D). In addition, while FIG. 3 depicts steps performed in a particular order for purposes of illustration and discussion, the methods discussed herein are not limited to any particular order or arrangement.
[0130] The method 200 may include, at block 202, providing a porous pouch. In aspects, the porous pouch may define a first end and a second end. The second end may be pre-sealed, while the first end defines an opening to permit access to an inner cavity of the porous pouch.
[0131] The method 200 may further include, at block 204, providing a composition. In aspects, providing the composition may include mixing or blending a plurality of active agents to form a powder composition. To fully enable the treatment of various oral conditions, the step of providing the composition may include selectively formulating the composition according to a target clinical indication. For instance, when manufacturing a pouch for the alleviation of xerostomia, providing the composition may include blending about 20 wt.% to about 80 wt.% of a sugar alcohol, about 0.5 wt.% to about 25 wt.% ofa mineralizing agent, about 0.5 wt.% to about 25 wt.% of a humectant, and a natural flavor agent
[0132] Additionally or alternatively, to manufacture a pouch for the treatment of aphthous ulcers, the step of providing the composition may include blending an analgesic, an antibacterial agent, an anti-inflammatory agent, and a humectant. In another aspect, to manufacture a pouch for post-surgical oral care, providing the composition may include blending a hemostatic agent, an anti-inflammatory agent, and a humectant. In yet another aspect, to manufacture a pouch for the treatment of halitosis, providing the composition may include blending an antibacterial agent, a humectant, and a probiotic.
[0133] The method 200 may include, at block 206, depositing the composition into the porous pouch via the opening defined by the first end of the porous pouch. In aspects, depositing the composition into the porous pouch may include measuring and depositing a targeted therapeutic dose based on the selected formulation. For instance, depositing the composition may include depositing about 100 mg to about 10,000 mg of the composition into the porous pouch. Additionally or alternatively, depositing the composition may include depositing about 0.5 grams to about 2.0 grams of the composition into the porous pouch for treatment of an aphthous ulcer, about 1.0 gram to about 10.0 grams of the composition into the porous pouch for post-surgical treatment, or about 0.5 grams to about 1.0 gram of the composition into the porous pouch for the halitosis treatment.
[0134] The method 200 may include, at block 208, sealing the first end of the porous pouch. In aspects, sealing the first end may enclose the opening, thereby securely encapsulating the composition within the inner cavity of the porous pouch. The sealing step may be performed using ultrasonic welding, heat sealing, or other suitable bonding techniques configured to create a durable seal without degrading the active agents within the composition.
[0135] This written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to practice the invention, including making and using any devices or systems and performing any of the incorporated methods. The patentable scope of the invention is defined by the claimsand may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they include structural elements that do not differ from the literal language of the claims or if they include equivalent structural elements with insubstantial differences from the literal language of the claims.
Claims
WHAT IS CLAIMED IS:
1. An intraoral pouch, comprising:a porous pouch comprising a shell and an inner cavity; anda composition within the inner cavity of the porous pouch, the composition comprising:about 20 wt.% to about 80 wt.% xylitol;about 0.5 wt.% to about 25 wt.% nano-hydroxyapatite (nHA); and about 0.2 wt.% to about 25 wt.% hyaluronic acid.
2. The intraoral pouch of claim 1 , wherein the composition is a powder composition.
3. The intraoral pouch of claim 1 , wherein the composition comprises: about 40 wt.% to about 60 wt.% xylitol;about 1.0 wt.% to about 10 wt.% nano-hydroxyapatite (nHA);about 1.0 wt.% to about 10 wt.% hyaluronic acid; andabout 0.2 wt.% to about 1.0 wt.% citric acid.
4. The intraoral pouch of claim 1 , wherein the hyaluronic acid has a molecular weight of about 10,000 g / mol to about 1 ,000,000 g / mol.
5. The intraoral pouch of claim 4, wherein the hyaluronic acid has a molecular weight of about 10,000 g / mol to about 100,000 g / mol.
6. The intraoral pouch of claim 1 , wherein the hyaluronic acid has a particle size of about 1 urn to about 100 urn.
7. The intraoral pouch of claim 1 , wherein the nano-hydroxyapatite has a particle size of about 20 nm to about 200 nm.
8. The intraoral pouch of claim 2, wherein the citric acid has a particle size of about 50 um to about 100 um.
9. The intraoral pouch of claim 1 , wherein the composition further comprises at least one of a binder, natural flavor agent, a sweetener, a flow agent, a buffering agent, or a moisture control agent.
10. The intraoral pouch of claim 9, wherein the flow agent comprises rice hull powder, silicon dioxide, or maltodextrin.
11. The intraoral pouch of claim 10, wherein the flow agent comprises rice hull powder having a particle size of about 50 um to about 500 um.
12. The intraoral pouch of claim 9, wherein the natural flavor agent comprises mint or citric acid.
13. The intraoral pouch of claim 9, wherein the sweetener comprises Stevia rebaudiana or monk fruit.
14. The intraoral pouch of claim 13, wherein the sweetener comprises Stevia rebaudiana and has a particle size of about 1 um to about 50 um.
15. The intraoral pouch of claim 9, wherein the buffering agent comprises sodium bicarbonate or magnesium carbonate.
16. The intraoral pouch of claim 9, wherein the moisture control agent comprises water, MCT oil, glycerin, or a combination thereof.
17. The intraoral pouch of claim 1 , further comprising:microcrystalline cellulose having a particle size of about 1 um to about 300 um.
18. The intraoral pouch of claim 1 , wherein the composition further comprises less than about 1 wt.% Aloe vera powder.
19. The intraoral pouch of claim 1 , wherein the shell of the porous pouch defines a pore size of about 20 urn to about 200 urn.
20. The intraoral pouch of claim 1 , wherein the shell of the porous pouch comprises a biocompatible fiber.
21. The intraoral pouch of claim 20, wherein the biocompatible fiber comprises cellulose, com fiber, or a biodegradable polymer.
22. The intraoral pouch of claim 20, wherein the porous pouch comprises a non-woven semi-permeable membrane formed from the biocompatible fiber.
23. The intraoral pouch of claim 1 , wherein a ratio of a width of the porous pouch to a length of the porous pouch is in a range from about 1 :2 to about 1 :2.5.
24. The intraoral pouch of claim 1 , wherein the intraoral pouch is free from tobacco and nicotine.
25. A method of manufacturing an intraoral pouch, the method comprising: providing a porous pouch, the porous pouch defining a first end and a second end, the second end being sealed and the first end defining an opening;providing a composition;depositing the composition into the porous pouch via the opening defined by the first end of the porous pouch; andsealing the first end of the porous pouch,wherein the composition comprises:about 20 wt.% to about 80 wt.% of a sugar alcohol;about 0.5 wt.% to about 25 wt.% of a mineralizing agent;about 0.5 wt.% to about 25 wt.% of a humectant; anda natural flavor agent.
26. The method of claim 25, wherein the composition is a powder composition.
27. The method of claim 25, wherein the sugar alcohol comprises xylitol.
28. The method of claim 25, wherein the mineralizing agent comprises nanohydroxyapatite (nHA).
29. The method of claim 25, wherein the humectant comprises hyaluronic acid.
30. The method of claim 25, wherein the step of depositing the composition into the porous pouch comprises depositing about 100 mg to 10,000 mg of the composition into the porous pouch.
31. The method of claim 25, wherein the composition further comprises at least one of a sweetener, a flow agent, a buffering agent, or a moisture control agent.
32. A composition for oral health, the composition comprising:about 20 wt.% to about 80 wt.% of a sugar alcohol;about 0.5 wt.% to about 25 wt.% of a mineralizing agent; and about 0.2 wt.% to about 25 wt.% hyaluronic acid.
33. The composition of claim 32, wherein the composition is an \powder composition.
34. The composition of claim 32, wherein the sugar alcohol comprises xylitol.
35. The composition of claim 32, wherein the mineralizing agent comprises nano-hydroxyapatite (nHA).
36. The composition of claim 32, wherein the hyaluronic acid has a molecular weight of about 10,000 g / mol to about 1 ,000,000 g / mol.
37. The composition of claim 32, wherein the composition comprises: about 40 wt.% to about 60 wt.% of the sugar alcohol;about 1.0 wt.% to about 10 wt.% of the mineralizing agent; andabout 1.0 wt.% to about 10 wt.% hyaluronic acid.
38. The composition of claim 37, wherein the composition further comprises: about 0.2 wt.% to about 1.0 wt.% of a natural flavor agent, the natural flavor agent comprising mint or citric acid.
39. The composition of claim 32, wherein the mineralizing agent comprises nano-hydroxyapatite having a particle size of about 20 nm to about 200 nm, and the hyaluronic acid has a particle size of about 1 urn to about 100 urn.
40. The composition of claim 32, further comprising at least one of a natural flavor agent, a sweetener, a flow agent, a buffering agent, or a moisture control agent.
41. An intraoral pouch for treatment of aphthous ulcers, the intraoral pouch comprising:a porous pouch defining a shell and an inner cavity;a composition within the inner cavity of the porous pouch, the composition comprising:about 0.25 wt.% to about 10.0 wt.% of an analgesic;about 5.0 wt.% to about 80.0 wt.% of an antibacterial agent; an anti-inflammatory agent; anda humectant.
42. The intraoral pouch of claim 41 , wherein the analgesic comprises benzocaine, a natural anesthetic, or a combination thereof.
43. The intraoral pouch of claim 41 , wherein the humectant comprises hyaluronic acid, hydroxypropyl cellulose, or a combination thereof.
44. The intraoral pouch of claim 41 , wherein the antibacterial agent comprises zinc acetate, xylitol or a combination thereof.
45. The intraoral pouch of claim 41 , wherein the anti-inflammatory agent comprises glycyrrhizin, curcumin, Boswellia extract, ora combination thereof.
46. The intraoral pouch of claim 41 , further comprising a soothing agent, the soothing agent comprising Aloe vera, chamomile, or a combination thereof.
47. The intraoral pouch of claim 41 , wherein the composition further comprises a buffering agent, the buffering agent comprising magnesium carbonate, sodium bicarbonate, or a combination thereof.
48. The intraoral pouch of claim 41 , wherein the composition further comprises a filler, the filler comprising microcrystalline cellulose.
49. The intraoral pouch of claim 41 , wherein the composition further comprises a binder, the binder comprising MCT oil, glycerin, ora combination thereof.
50. The intraoral pouch of claim 41 , wherein the composition has a total weight of about 0.5 grams to about 2.0 grams.
51. An intraoral pouch for post-surgical oral care, the intraoral pouch comprising:a porous pouch defining a shell and an inner cavity; anda composition within the inner cavity of the porous pouch, the composition comprising:about 0.01 wt.% to about 5.0 wt.% of a hemostatic agent;an anti-inflammatory agent; anda humectant.
52. The intraoral pouch of claim 51 , wherein the humectant comprises hyaluronic acid.
53. The intraoral pouch of claim 51 , wherein the hemostatic agent comprises chitosan, calcium carbonate, tannic acid, alginate, kaolin, or a combination thereof.
54. The intraoral pouch of claim 53, wherein the hemostatic agent comprises about 0.1 wt.% to about 5.0 wt.% of chitosan, about 0.1 wt.% to about 5.0 wt.% of calcium carbonate, about 0.01 wt.% to about 0.5 wt.% of tannic acid, about 0.1 wt.% to about 3.0 wt.% of alginate, about 0.1 wt.% to about 3.0 wt.% of kaolin, or a combination thereof.
55. The intraoral pouch of claim 51 , wherein the anti-inflammatory agent comprises curcumin, Boswellia extract, Aloe vera, or a combination thereof.
56. The intraoral pouch of claim 51 , wherein the composition further comprises an analgesic, the analgesic comprising benzocaine, clove oil, or a combination thereof.
57. The intraoral pouch of claim 51 , wherein the composition further comprises an antibacterial agent comprising xylitol, acetic acid, or a combination thereof.
58. The intraoral pouch of claim 51 , wherein the composition further comprises a buffering agent, the buffering agent comprising magnesium carbonate, sodium bicarbonate, or a combination thereof.
59. The intraoral pouch of claim 51 , wherein the composition further comprises a binder, the binder comprising hydroxypropyl cellulose-L, MCT oil, glycerin, or a combination thereof.
60. The intraoral pouch of claim 51 , wherein the composition further comprises a filler, the filler comprising microcrystalline cellulose.
61. The intraoral pouch of claim 51 , wherein the composition has a total weight of about 1.0 gram to about 10.0 grams.
62. An intraoral pouch for the treatment of halitosis, the intraoral pouch comprising:a porous pouch defining a shell and an inner cavity; anda composition within the inner cavity of the porous pouch, the composition comprising:about 20.0 wt.% to about 85.0 wt.% of an antibacterial agent; about 0.2 wt.% to about 5.0 wt.% of a humectant; anda probiotic.
63. The intraoral pouch of claim 62, wherein the antibacterial agent comprises xylitol.
64. The intraoral pouch of claim 63, wherein the antibacterial agent further comprises zinc acetate, zinc gluconate, or a combination thereof.
65. The intraoral pouch of claim 62, wherein the humectant comprises hyaluronic acid.
66. The intraoral pouch of claim 62, wherein the probiotic comprises Streptococcus salivarius K12, Weissella cibaria, or a combination thereof.
67. The intraoral pouch of claim 62, wherein the probiotic is present in an amount from 10 billion colony-forming units (CFU) to 300 billion CFU.
68. The intraoral pouch of claim 62, wherein the composition comprises a moisture content of about 0% to about 20%.
69. The intraoral pouch of claim 62, wherein the composition further comprises a binder, the binder comprising hydroxypropyl cellulose-L, MCT oil, glycerin, or a combination thereof.
70. The intraoral pouch of claim 62, wherein the composition further comprises citric acid.
71. The intraoral pouch of claim 62, wherein the composition further comprises a filler, the filler comprising microcrystalline cellulose.
72. The intraoral pouch of claim 62, wherein the composition further comprises a sweetener, the sweetener comprising Stevia rebaudiana.
73. The intraoral pouch of claim 62, wherein the composition has a total weight of about 0.5 grams to about 1.0 gram.
